The Biotech Barbie Taking On Human Gene Editing
Katie Tai calls herself "biotech Barbie." At 29, she's launching what might be the most controversial startup of her career: Manhattan Genomics, a company planning to edit human embryo genomes using CRISPR-Cas9 technology to prevent genetic disorders before birth.
The name is a deliberate provocation. Just as the Manhattan Project ushered in the atomic age with all its promise and peril, Tai believes her new venture will force society to confront the power—and responsibility—of rewriting human DNA at its earliest stage.
A Serial Entrepreneur Enters Uncharted Territory
Tai's path to this frontier began at 18, when she dropped out of university to establish her first biotechnology company. Over the following 11 years, she founded several startups focused on genetic test result analysis and digital healthcare services. Each venture built her expertise in translating complex genomics into practical applications.
But Manhattan Genomics, founded this summer with Eriona Hysollj—former head of biological sciences at Colossal Biosciences, the Texas startup working to revive extinct species like mammoths—represents a leap into far more contentious terrain.
The Technology and the Stakes
CRISPR-Cas9 is a molecular tool that acts like programmable scissors for DNA, allowing scientists to cut and modify specific genes with unprecedented precision. The technology has already revolutionized research and enabled treatments for blood diseases in children and adults.
Editing embryo genomes, however, is different. Changes made at this stage would be permanent and heritable, passing to future generations. This raises profound questions: Which conditions justify intervention? Who decides what counts as a disorder versus natural human variation? What happens if unintended consequences emerge years later?
Tai argues that most Americans support gene editing technology, though she hasn't disclosed Manhattan Genomics' specific plans yet. According to her, the company will conduct extensive research and safety trials before attempting any human embryo modifications.
Building Guardrails
The startup's early hires reveal an awareness of these concerns. Among Manhattan Genomics' first employees are a bioethics specialist and two scientists specializing in reproductive biology of non-human primates. Their mandate: verify the technology's safety before it touches a human embryo.
These precautions may not satisfy critics. Many researchers believe commercial human gene editing is premature, carrying safety risks and ethical complexities that current animal studies and adult gene therapies haven't resolved. The scientific consensus remains that embryo genome editing technology needs more research before anyone can confirm its safety and feasibility.
Innovation Versus Oversight
Tai's trajectory embodies the tension at the heart of biotechnology today. Entrepreneurs like her move fast, driven by vision and venture capital, pushing boundaries that regulations struggle to keep pace with. The tools exist; the scientific understanding is advancing rapidly; the business models are forming.
But unlike software or consumer products, mistakes in human genome editing can't be patched with an update. The stakes are generational.
As Manhattan Genomics moves from stealth mode to active research, it will test whether the biotech industry can balance Tai's entrepreneurial urgency with the deliberate caution that altering human inheritance demands. The "biotech Barbie" moniker might be playful, but the questions her work raises are anything but.
Whether society is ready for companies like Manhattan Genomics—and whether Manhattan Genomics is ready for the responsibility it's claiming—remains to be seen.
